➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Colorcon
AstraZeneca
Boehringer Ingelheim
Express Scripts

Last Updated: October 26, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VINCASAR PFS

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Vincasar Pfs

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT03742258 Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Not yet recruiting National Cancer Institute (NCI) Phase 1 2018-12-29 The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL). ?Investigational? means that TAK-659 has not been approved by the United States Food and Drug Administration (FDA) for use as a prescription or over-the-counter medication to treat a certain condition. The primary purpose of this study is to find the appropriate and safe dose of the study drug to be used in combination with standard chemotherapy for the treatment of your disease and to determine how well the drug works in treating your disease. Other objectives include measuring the amount of the study drug in your body at different times after taking the study drug. Your participation in the study is expected to last for up to 3 years after receiving the last dose of the study drug. You will receive the study treatment for up to 18 weeks, as long as you are benefitting.
OTC NCT03742258 Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Not yet recruiting Northwestern University Phase 1 2018-12-29 The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL). ?Investigational? means that TAK-659 has not been approved by the United States Food and Drug Administration (FDA) for use as a prescription or over-the-counter medication to treat a certain condition. The primary purpose of this study is to find the appropriate and safe dose of the study drug to be used in combination with standard chemotherapy for the treatment of your disease and to determine how well the drug works in treating your disease. Other objectives include measuring the amount of the study drug in your body at different times after taking the study drug. Your participation in the study is expected to last for up to 3 years after receiving the last dose of the study drug. You will receive the study treatment for up to 18 weeks, as long as you are benefitting.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Vincasar Pfs

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00390793 Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL Active, not recruiting Bristol-Myers Squibb Phase 2 2006-09-01 The goal of this clinical research study is to find out if intensive chemotherapy combined with dasatinib, followed by maintenance therapy, can help to control ALL with the Ph chromosome and/or BCR-ABL. The safety of this treatment will also be studied.
NCT00390793 Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL Active, not recruiting M.D. Anderson Cancer Center Phase 2 2006-09-01 The goal of this clinical research study is to find out if intensive chemotherapy combined with dasatinib, followed by maintenance therapy, can help to control ALL with the Ph chromosome and/or BCR-ABL. The safety of this treatment will also be studied.
NCT02043587 Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Recruiting Sigma Tau Pharmaceuticals, Inc. Phase 2 2014-01-01 The objective of this protocol is to improve survival for adults with acute lymphoblastic leukemia or acute lymphoblastic lymphoma by reducing systemic and central nervous system (CNS) relapse with acceptable toxicity using intensive chemotherapy with liposomal cytarabine (Depocyt®) CNS prophylaxis.
NCT02043587 Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Recruiting University of California, San Diego Phase 2 2014-01-01 The objective of this protocol is to improve survival for adults with acute lymphoblastic leukemia or acute lymphoblastic lymphoma by reducing systemic and central nervous system (CNS) relapse with acceptable toxicity using intensive chemotherapy with liposomal cytarabine (Depocyt®) CNS prophylaxis.
NCT02660762 Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL Recruiting Sun Yat-sen University Phase 2 2010-01-01 This prospective study was conducted to evaluate the efficacy and safety profiles of Modified MRCUKALLⅫ/ECOGE2993 Regimen in young adults with newly diagnosed, low-risk, Philadelphia chromosome negative acute lymphoblastic leukaemia.
NCT03007147 Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Not yet recruiting National Cancer Institute (NCI) Phase 3 2017-07-01 This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
NCT03007147 Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Not yet recruiting Children's Oncology Group Phase 3 2017-07-01 This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vincasar Pfs

Condition Name

Condition Name for Vincasar Pfs
Intervention Trials
Diffuse Large B-Cell Lymphoma 4
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements 3
High Grade B-Cell Lymphoma, Not Otherwise Specified 3
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Vincasar Pfs
Intervention Trials
Lymphoma 13
Leukemia 11
Precursor Cell Lymphoblastic Leukemia-Lymphoma 10
Leukemia, Lymphoid 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Vincasar Pfs

Trials by Country

Trials by Country for Vincasar Pfs
Location Trials
United States 42
Tanzania 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Vincasar Pfs
Location Trials
Washington 3
Illinois 3
Pennsylvania 3
Virginia 2
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Vincasar Pfs

Clinical Trial Phase

Clinical Trial Phase for Vincasar Pfs
Clinical Trial Phase Trials
Phase 3 7
Phase 2/Phase 3 2
Phase 2 6
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Vincasar Pfs
Clinical Trial Phase Trials
Not yet recruiting 17
Recruiting 6
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Vincasar Pfs

Sponsor Name

Sponsor Name for Vincasar Pfs
Sponsor Trials
National Cancer Institute (NCI) 20
Children's Oncology Group 4
University of Washington 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Vincasar Pfs
Sponsor Trials
Other 23
NIH 20
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Merck
Baxter
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.